Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
Browsing: Science
Researchers in Japan have identified a promising possibility in LPC70, a compound derived from soy. Previous research found that this ingredient could reduce high blood pressure and cognitive problems associated with a high-salt diet (HSD) in mice. The latest study takes a closer look at how it works, revealing that the compound influences important chemical signals in the brain and kidneys.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
Researchers in Japan have identified a promising possibility in LPC70, a compound derived from soy. Previous research found that this ingredient could reduce high blood pressure and cognitive problems associated with a high-salt diet (HSD) in mice. The latest study takes a closer look at how it works, revealing that the compound influences important chemical signals in the brain and kidneys.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage.
Watch a subscriber-only conversation with one of MIT Technology Review's Innovators Under 35.
The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage.